UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) (ZIP Code)
Registrant’s telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On November 14, 2023, Salona Global Medical Device Corporation (the "Company") issued a press release announcing its attendance at the Medica 2023 annual conference to be held in Dusseldorf, Germany from November 13, 2023 through November 16, 2023, which press release was filed via the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval (SEDAR). The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No | Description |
| 99.1 | Press Release of Salona Global Medical Device Corporation dated November 14, 2023. |
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| SALONA GLOBAL MEDICAL DEVICE CORPORATION | ||
| Date: November 14, 2023 | By: | /s/ Natalia Vakhitova |
| Name: Natalia Vakhitova | ||
| Title: Chief Financial Officer | ||
EXHIBIT 99.1
Salona Global Showcases Biodex Products at Medica Trade Fair in Düsseldorf, Germany;
Expanding Access to International Markets
New York, New York, November 14, 2023 - Salona Global Medical Device Corporation (the "Company") (TSXV:SGMD), soon to be renamed Evome Medical Technologies Inc., announced its attendance at Medica 2023 which is held annually in Dusseldorf, Germany. Being one of the premier events in the medical industry around the globe it allows the Company to showcase its products to the industry professionals and connect with potential customers and distributors/strategic partners abroad. CEO Mike Seckler will host a series of events and meetings with the aim of increasing access to untapped international markets for the Company's Biodex Rehab line of medical devices and its Mio-Guard line of medical and athletic supplies.
The Company's Biodex Rehab and Mio-Guard divisions are moving forward with collaborating in providing comprehensive services to physical therapy and sports rehabilitation clinics. While Biodex Rehab continues its focus on delivering science-based solutions for rehabilitation exercise and injury recovery segment, Mio-Guard serves as a reliable supplier of sports medicine supplies. Together, they will excel in offering an integrated approach to support the diverse needs of clinics in the field of Physical Medicine.
"Continuing with our accomplishment in the Polish marketplace, I have made international sales our priority. We have a stellar brand name coupled with a unique product lineup that I believe holds significant appeal for international markets were we have not previously excelled in contribution of marketing efforts. A major part of our revenue growth plan for 2024, especially in the first half of the year is expected to come from international markets that are in need of our devices. Finding and securing qualified distributors/strategic partners and new customers during our attendance of the world's leading trade show is the key to executing on this plan."
For more information please contact:
Mike Seckler
Chief Executive Officer
Tel: 1 (800) 760-6826
Email: Info@Salonaglobal.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Document and Entity Information Document |
Nov. 14, 2023 |
|---|---|
| Document Information [Line Items] | |
| Document Type | 8-K |
| Document Creation Date | Nov. 14, 2023 |
| Document Period End Date | Nov. 14, 2023 |
| Amendment Flag | false |
| Entity Registrant Name | Salona Global Medical Device Corp. |
| Entity Address, Address Line One | 49 Natcon Dr |
| Entity Address, City or Town | Shirley |
| Entity Address, State or Province | NY |
| Entity Address, Country | US |
| Entity Address, Postal Zip Code | 11967 |
| Entity Incorporation, State Country Name | A1 |
| City Area Code | 800 |
| Local Phone Number | 760-6826 |
| Entity File Number | 333-255642 |
| Entity Central Index Key | 0001617765 |
| Entity Emerging Growth Company | true |
| Entity Tax Identification Number | 00-0000000 |
| Entity Ex Transition Period | false |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |